Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Early Study Termination Is Key Issue In ODAC Review Of Pfizer's Sutent For Pancreatic Cancer

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA is asking its Oncologic Drugs Advisory Committee whether sunitinib's risk/benefit profile in pancreatic neuroendocrine tumors is favorable given that early termination of the Phase III trial created uncertainty about the magnitude of its progression-free survival benefit.
Advertisement

Related Content

Sutent Cleared For Pancreatic Tumors, But With Caveat On Efficacy
Sutent Cleared For Pancreatic Tumors, But With Caveat On Efficacy
Sutent Pancreatic Tumor Study Shows Regulatory Pitfalls Of Stopping Early
Pfizer's Sutent, Novartis' Afinitor Earn ODAC Backing For Pancreatic Tumors
Discordant Trial Results Among Issues FDA Bringing To Advisory Panel Review Of Novartis' Afinitor
FDA Sends Sutent sNDA For Pancreatic Cancer To ODAC
FDA's Avastin Decision Puts Pressure On Progression-Free Survival Endpoints
Toxicity Of AstraZeneca's Vandetanib Expected Focus For FDA Advisory Committee
Pfizer Clears Out Pipeline: After Oncology Disappointments, Talks Up Diabetes
Pfizer Clears Out Pipeline: After Oncology Disappointments, Talks Up Diabetes

Topics

Advertisement
UsernamePublicRestriction

Register

PS072083

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel